The therapeutic utility of endothelial progenitor cells (EPCs) in cardiovascular disease is potentially hampered by their low numbers in the circulation, impaired functional activity, and inhibitory factors in the recipient. These obstacles can possibly be circumvented by the use of proangiogenic cytokines and peptides. We sought to examine the effect of the endogenous vasoactive peptide adrenomedullin (AM) on the angiogenic potential of late outgrowth EPCs and their release of proangiogenic and proinflammatory cytokines/chemokines. Human peripheral blood mononuclear cells were cultured until the appearance of typical late outgrowth EPC colonies. The effect of AM on EPC proliferation was assessed using a colorimetric MTS proliferation assay while differentiation and formation of tubular structures in an EPC/fibroblast coculture or matrigel assay was used to assess the angiogenic potential of the cells. Finally, the release and mRNA transcripts of cytokines/chemokines were quantified in stimulated vs. nonstimulated EPCs using real-time PCR and a bead-based multiplex assay. The cultured EPCs possessed an endothelial phenotype and expressed the AM receptor (calcitonin receptor-like receptor/receptor activity modifying protein-2). AM stimulation induced proliferation of EPCs compared with controls (P Ͻ 0.05). Furthermore, AM produced a 36% and 80% increase in the formation of tubular networks in the EPC/fibroblast coculture and matrigel assay, respectively (P Ͻ 0.05). These effects seemed to be mediated through the phosphatidylinositol 3-kinase/Akt signaling pathway.
levels of cell survival and poor engraftment of the transplanted cells (15, 43, 51, 56) . These obstacles can possibly be circumvented by ex vivo priming of harvested cells or cotreatment with proangiogenic cytokines and peptides.
Since Asahara et al. (3) first reported the existence of circulating endothelial progenitor cells, at least two phenotypes have been described based on different morphology, function, and growth potential (18, 21, 31) . The late outgrowth EPCs (late EPCs) differ from early outgrowth EPCs (early EPCs) in having a high proliferative capacity and that they do not express the hematopoetic markers CD14 and CD45 (55) . Recent studies indicate a limited degree of engraftment and incorporation into new vessels from early EPCs (2, 55) , and it has been proposed that they exert their proangiogenic activity mainly through secretion of angiogenic factors (18, 40, 41, 49) . Late EPCs are, however, much less studied. Despite favorable in vitro angiogenic properties compared with other putative EPCs (45) and their capacity to form de novo vessels in vivo (42, 55) , no studies have so far been performed in humans.
Adrenomedullin (AM) is a 52 amino acid endogenous vasoactive peptide synthesized in most tissues including vascular endothelial cells. Elevated levels have been reported in several disease states including acute myocardial infarction and heart failure (16) . The systemic vascular effects of AM are characterized by vasodilation and hypotension (22) . In addition, AM displays a variety of biological actions suggesting that it acts protectively against vascular damage and progression of atherosclerosis (25) . The endothelial effects include reduction of endothelial permeability (17) , inhibition of endothelial apoptosis (24) , and promotion of endothelial proliferation (26, 33) . Of particular importance for the aim of this study, AM has also been shown to promote angiogenesis in various experimental models (1, 20, 36) .
The effect of AM on endothelial cells is mediated through a seven-transmembrane G protein-coupled receptor, the calcitonin receptor-like receptor (CRLR), and the receptor activitymodifying protein 2 and 3 (RAMP), generating the AM1 and AM2 receptor, respectively (32, 39) . Of importance, RAMP-2 is critical for the vascular and angiogenic properties of AM (13, 19) . The proliferative and proangiogenic properties of AM seem to be mediated through activation of the phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), and p125 FAK signaling pathways in endothelial cells (26, 34) .
The beneficial effects on the vasculature and endothelium along with the proangiogenic properties make AM an ideal candidate to improve the utility of EPC transplantation. The aim of the present study was therefore to clarify whether AM can promote the growth potential of cultured late EPCs and to assess whether AM also increases their angiogenic potential. Finally, we examined whether AM would induce release of proangiogenic cytokines and chemokines from the EPCs and thereby promote their paracrine and chemo-"self"-attractant effects.
MATERIALS AND METHODS
The study and collection of blood from healthy volunteers (n ϭ 8) was approved by the regional ethics committee (REK-Nord 51/2004) and conformed to the principles outlined in the Declaration of Helsinki.
Isolation and culture of cells. Human mononuclear cells (MNCs) were isolated from 36 ml heparinized blood. Blood was diluted 1:1 with phosphate-buffered saline (PBS) and was added onto Ficollpaque plus (Amersham Biosciences, Uppsala, Sweden). MNCs were isolated by centrifugation at 740 g for 30 min at room temperature and washed twice with PBS. After resuspension in endothelial growth medium 2 (EGM-2; Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum (FBS; Biochrom, Berlin, Germany), cell numbers were quantified using Sysmex K1000 (TAO Medical Electronics). Cells were seeded at 5 ϫ 10 6 cells/well onto six-well plates precoated with rat tail collagen type 1 (BD Biosciences, Bedford, MA) and cultured at 37°C, 5% CO2. After 24 h, nonadherent cells were removed, and medium was replaced with fresh EGM-2 supplemented with 10% FBS. The medium was changed daily for 6 days and then every other day until the appearance of typical late EPC colonies with cobblestone morphology (for a maximum of 3 wk). Cells in passage 3-8 were used in all the experiments. Human umbilical vein endothelial cells (HUVEC, Lonza, Verviers, Belgium) at passage 3-8 were cultured in EGM-2 supplemented with 10% FBS in culture flasks precoated with rat tail collagen. Culture medium was changed every 2-3 days, and cells were split at 90% confluence. No tests were performed to rule out mycoplasmal contamination.
Phenotypic characterization of EPCs. The following antibodies were used for immunostaining: mouse anti-human VE-cadherin (CD144) antibody (R&D systems, Abingdon, UK), mouse anti-human CD31 (PECAM-1) antibody (R&D Systems, Abingdon, UK), rabbit anti-human CRLR antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-human RAMP-2 antibody (Santa Cruz Biotechnology). Secondary antibodies were as follows: Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, Eugene, OR). Uptake of acetylated-LDL was assessed using Dil-Ac-LDL (acetylated low-density lipoprotein labeled with 1,1=-dioctadecyl-3,3,3=,3=-tetramethylindo-carbocyanine perchlorate; Biomedical Technologies, Stoughton, MA). Draq5 (Biostatus, Shepshed, UK) was used for nuclei staining.
Cell proliferation assays. EPC proliferation was assessed using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI), a colorimetric determination of viable cells based on the bioreduction of a tetrazolium compound (MTS; [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]) in metabolically active cells. Cells were seeded on a 96-well plate in triplicate at 5 ϫ 10 3 cells/well and treated for 48 h using control medium EBM (endothelial basal media) supplemented with 2% FBS or the addition of either AM (10 Ϫ7 mol/l, Sigma-Aldrich, Schnelldorf, Germany), vascular endothelial growth factor (VEGF; 50 ng/ml, BD Biosciences), or both AM and VEGF (doses as above). Dosing was chosen on the basis of dose-response experiments for AM ( Fig. 2A) , and previous reports suggesting that the maximal stimulatory effect on endothelial cells is reached at these concentrations (9, 13, 33) . Also, increasing the concentration of VEGF (100 ng/ml) did not further increase proliferation in our study (not shown). In addition, the AM receptor antagonist, adrenomedullin fragment 22-52 (AM 10 Ϫ6 mol/l); PI3K inhibitor, wortmannin (500 nmol/l); and the mitogen-activated protein/extracellular signalregulated kinase kinase (MEK1/2) inhibitor, U0126 (20 mol/l) (all from Sigma-Aldrich, St. Louis, MO), were added in separate experiments to AM-stimulated wells (2 h preincubation with inhibitors). Plates were read at 490 nm in a microplate reader after incubation with the MTS reagent at a 1:5 concentration for 2.5 h.
In vitro angiogenesis assay. The angiogenic effects of AM and VEGF on EPCs was assessed using a previously described coculture assay (4, 45) . Human fibroblasts (MRC5) were seeded onto a 24-well culture plate and allowed to grow to confluence. EPCs (1 ϫ 10 4 ) were added, and cocultures were grown for 14 days in EGM-2 (without VEGF) with the addition of either of AM (10 Ϫ7 mol/l) or VEGF (50 ng/ml). AM-binding protein 1 (AMBP-1, complement factor H) is a specific AM-binding protein believed to modulate the biological effects of AM and has been shown to further increase the proliferation of cancer cell lines when coadministered with AM (38) . To examine whether this interaction could influence the proangiogenic effects of AM, AMBP-1 (5 ϫ 10 Ϫ8 mol/l, Fitzgerald Industries, Concord, MA) was added in three experiments. Cell cultures were fixed with 4% paraformaldehyde, washed with PBS, and incubated with PBS 1% goat serum before incubation with mouse anti-human CD31 followed by Alexa Fluor 488 goat anti-mouse IgG. Tubular networks were photographed with an inverted fluorescence microscope (Eclipse TE300, Nikon, Japan). In addition, 6 ϫ 10 4 EPCs/well were seeded in duplicate onto a 24-well plate coated with 100 l Growth Factor Reduced Matrigel Matrix (BD Biosciences). Cells were treated with EBM supplemented with 2% FBS with the addition of either AM (10 Ϫ7 mol/l), VEGF (50 ng/ml), AM plus VEGF, or AM with addition of the inhibitors AM 22-52 (10 Ϫ6 mol/l), wortmannin (500 nmol/l), and U0126 (20 mol/l). Cells were preincubated with inhibitors 2 h before the addition of AM. Increasing the concentration of AM and VEGF, as for proliferation studies, did not further increase tubule formation (not shown). After 18 h incubation at 37°C, plates were photographed at ϫ40 magnification using an inverted light microscope. The extent of tubular networks in both assays was analyzed using Scion Image software and are presented as percentage of control.
RNA isolation and cDNA synthesis. EPC and HUVEC cells were harvested using trypsin/EDTA (0.05%/0.02%, Biochrom). The cells were seeded onto six-well culture plates precoated with rat tail collagen at a concentration of 2 ϫ 10 5 cells in EGM-2 with 10% FBS. Once confluent, EGM-2 with 10% FBS was replaced with EBM-2. After 2 h, cells were stimulated with AM (10 Ϫ7 mol/l), VEGF (50 ng/ml), or the combination of the two in EBM-2 supplemented with 2% FBS at 37°C and 5% CO2. After 2 and 20 h, total RNA was isolated from the cells by PerfectPure RNA isolation kit (5 Prime, Hamburg, Germany). Reverse transcription of RNA was carried out in a 20 l final volume from 400 ng total RNA using a cDNA Synthesis Kit (Applied Biosystems, Foster City, CA). Finally, cDNA was diluted 1:8 before use in real-time quantitative PCR.
Real-time PCR. Real-time PCR was performed in an ABI PRISM 7900 HT Fast real-time thermal cycler using the TaqMan Fast Universal PCR master mix (Applied Biosystems). The primer/probe sequences for the genes studied are given in Supplemental Table S1 (Supplemental Material for this article is available online at the Journal website). Primers and TaqMan probes were obtained from Eurogentec (Seraing, Belgium), and 2 l of cDNA corresponding to 5 ng of total RNA was used in a 10 l final volume. Samples were heated for 20 s at 95°C and then subjected to a 40 cycles of denaturation at 95°C for 1 s and annealing and elongation at 60°C for 20 s. A negative control without cDNA template was included in every assay. The PCR efficiency for all genes was determined by performing a dilution series of a pool of all samples. The efficiency (E) was then calculated from the slope of the plot of C t (cycle threshold) vs. log dilution series ("number of amplicon") according to the established equation:
The relative expression ratio of the target genes was calculated on the basis of its real-time efficiency and the Ct differences (⌬) of a treated sample versus a control sample (37) . The stability of selected reference genes (HPRT1, GAPDH, cyclophilin, tubulin, RPL13a, B2M) was measured by geNorm (50) . The results from this analysis revealed HPRT1 as a stably expressed gene in EPCs and MNCs. RPL13a was a stably expressed gene in EPCs after short-term stimulation (2-20 h) with VEGF or AM. The expression of the target genes mRNA was normalized to the stably expressed reference gene HPRT1 or RPL13A or GAPDH. Determination of proangiogenic cytokines. EPCs (n ϭ 5) were cultured on six-well plates until confluent. After washing and 2 h incubation in EBM, cells were incubated 2, 4, 8, and 20 h in EBM (2% FBS) with the addition of either AM (10 Ϫ7 mol/l), VEGF (50 ng/ml), or the combination of the two. The conditioned medium was withdrawn, centrifuged at 1,450 g, and stored until analysis at Ϫ70°C. The secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), stromal cellderived factor 1 (SDF-1), and VEGF was quantified in duplicate using a bead-based multiplex assay (Bioplex, Bio-Rad Laboratories, Hercules, CA). Concentration of cytokines was calculated using Bioplex software.
Statistical analysis. The data are expressed as means Ϯ SD. Data were analyzed using paired t-tests or repeated-measures ANOVA with Bonferroni correction for multiple comparisons for normally distributed data. Nonnormally distributed data were analyzed using a Wilcoxon signed-rank test. Two-sided P values Ͻ 0.05 were considered to be significant. All data were analyzed using SPSS software (version 16.0; SPSS, Chicago, IL). (Fig. 1) . These findings were also supported by real-time PCR mRNA analysis showing expression of these markers equivalent to what is observed in HUVECs (Fig.  1G) . EPCs also stained positive for CRLR and RAMP-2 (Fig. 1,  B and C) . This was further demonstrated by the existence of the CRLR/RAMP-2 (AM1 receptor) complex at the mRNA level (Fig. 1G) . AM stimulation for respectively 48 h and 14 days did not alter the endothelial phenotype of these cells (Supplemental Fig. S1 ).
RESULTS

Late EPCs express the CRLR/RAMP-2 (AM1) receptor
Increased EPC proliferation in the presence of adrenomedullin. The results of the MTS proliferation assay are presented in Fig. 2 . AM increased EPC proliferation in a dose-dependent manner. This stimulated proliferation was suppressed by addition of the AM antagonist AM 22-52 (P ϭ 0.07, Fig. 1 . Endothelial progenitor cell (EPC) characterization. A: confluent layer of late outgrowth EPCs in culture. B and C: immunofluorescence staining: receptor activity modifying protein 2 (RAMP-2) (B) and calcitonin receptor-like receptor (CRLR) (C). Magnification, ϫ200. D and E: confocal photomicrographs: platelet endothelial cell adhesion molecule (PECAM; CD31) (D) and VE-cadherin (CD144) (E). Cell nuclei were counterstained with Draq5 (blue). F: uptake of Dil-Ac-LDL (acetylated low-density lipoprotein labeled with 1,1=-dioctadecyl-3,3,3=,3=-tetramethylindo-carbocyanine perchlorate). G: real-time PCR results of the relative mRNA expression of relevant genes to characterize EPCs (n ϭ 6) compared with human umbilical vein endothelial cells (HUVEC, n ϭ 1) and mononuclear cells (MNC, n ϭ 4). Data are presented as means Ϯ SD. *No expression. #P ϭ 0.001 compared with EPC. VEGFR-2, vascular endothelial growth factor (VEGF) receptor 2. Fig. 2C) . Additionally, the specific endothelial growth factor VEGF in the concentration of 50 ng/ml was more potent as a growth stimulator than both control and AM [mean optical density (OD mean ) ϭ 0.610, P Ͻ 0.001 and P ϭ 0.049]. A further increase in growth was observed for the combination of AM and VEGF (OD mean ϭ 0.647) compared with AM alone (P ϭ 0.006), but this was not significantly different compared with VEGF. Inhibition with wortmannin abolished the AM-induced proliferation (P ϭ 0.01) while no suppression was observed following addition of U0126 (P ϭ 0.63, Fig. 2C) .
Increased tubule formation following AM stimulation. The addition of AM produced a 36% relative increase in tubular network formation in the EPC/fibroblast coculture assay compared with control (Fig. 3) . Tubule formation was slightly more pronounced following VEGF stimuli (53% increase), but not significantly better than for AM. The same effect on tubule formation was also seen in the matrigel assay (Fig. 4) . However, the proangiogenic properties of VEGF were more apparent in the coculture assay as compared with the short-lasting matrigel assay. Increasing concentrations of AM (10 Ϫ6 mol/l) and VEGF (100 ng/ml) did not further increase the tubular network formation on matrigels (not shown). Also, coadministration of AM (10 Ϫ7 mol/l) with AMBP-1 (5 ϫ 10 Ϫ8 mol/l) in three experiments did not alter the extent of tubular formation compared with AM alone (not shown). Addition of AM 22-52 and wortmannin blunted the observed increase in tubule formation following AM stimuli (P ϭ 0.008 and 0.024, respectively, Fig. 4F ). Similar to the observations on AMinduced proliferation, addition of the MEK1/2 inhibitor U0126 did not suppress the increased tubule formation (P ϭ 0.71).
Secretion of proangiogenic and proinflammatory cytokines. AM did not seem to affect EPC release of VEGF or the VEGF mRNA expression (Fig. 5, A and B) . Also, the measured concentrations of VEGF in the conditioned media were minute compared with experimental concentrations normally used to induce an angiogenic response (10 -100 ng/ml vs. ϳ130 pg/ml in conditioned media). Both VEGF and SDF-1 levels were unchanged after 20 h incubation of nonstimulated EPCs (Fig.  5A and Supplemental Fig. S2G ). Furthermore, AM stimuli did not change the mRNA expression of VEGF receptor 2 (VEGFR-2) or the SDF-1 receptor, CXCR-4 (Fig. 5, C and D) .
Measured levels of IL-6 and IL-8 from nonstimulated EPCs increased in a time-dependent manner from 2 to 20 h (P ϭ 0.04 and P ϭ 0.003; Supplemental Fig. S2G ). There was an early augmentation of IL-6 and IL-8 secretion from AM-stimulated cells compared with control at 2 h, but this was not evident at 20 h (Supplemental Fig. S2, A and C) . This was further supported by an early twofold increase in the expression of IL-6 and IL-8 mRNA compared with control ( Supplemental  Fig. S2, B and C) . Simultaneous stimulation with AM and VEGF did not significantly add to the release of cytokines seen with either agent alone, although there was a tendency toward increased release and mRNA expression of IL-6 and IL-8, suggesting a possible additive stimulatory effect (Supplemental Fig. S2, B and D) . itor and stem cells. These studies have shown that AM suppresses apoptosis and increases the number of early EPCs (23, 29) . In the present study, we show that these findings also apply to the highly proliferative late EPCs. There is a growing amount of research documenting that these late outgrowth EPCs are the true progenitors of mature endothelial cells, and our observation is therefore important for the assessment of the potential role of adrenomedullin in EPC differentiation. Importantly, coadministration of AM augments the angiogenic effects of unspecified bone marrow-derived mononuclear cell transplantation in experimental models of ischemia (11, 23) . Also, the therapeutic effect of transplantation with AM-gene transduced EPCs proved superior compared with EPCs alone in a rat model of pulmonary endothelial injury (35) . These studies suggest a potent stimulatory role of AM in both EPCs and other cells with stem cell potential and thus its usefulness in therapeutic angiogenesis and vascular repair. This study demonstrates that late outgrowth endothelial progenitor cells express the CRLR/RAMP-2 (AM1) receptor complex. AM both enhances cell growth and the proangiogenic properties of these cells. Furthermore, these effects were counteracted by the AM receptor antagonist AM 22-52. The observed biochemical responses open for both in vitro and in vivo treatment potential for the hormone AM in cases of ischemia or endothelial damage. The AM-induced EPC proliferation and tubule formation seemed to be mediated through the PI3K/Akt signaling pathway as demonstrated by the inhibitory effects of wortmannin. This pathway regulates several important steps in angiogenesis including endothelial cell proliferation, migration, and capillary formation. PI3K/Akt also seem to mediate the antiapoptotic actions of AM on early EPCs (29) . While prior studies have demonstrated that AM also induces endothelial cell proliferation and angiogenesis through the activation of MAPK, this was, however, not evident in the EPCs in our study using the MEK1/2 inhibitor U0126 (26) . The addition of adrenomedullin-binding protein 1 (AMBP-1) did not enhance EPC tubule formation in cocultures with fibroblasts. This observation probably means that such a transporter protein is not mandatory in cell cultures, but the need for this transporter could potentially be concealed due to local secretion from the cocultured fibroblasts because human synovial fibroblasts have been shown to express and secrete AMBP-1 (10) .
In agreement with studies conducted on human umbilical cord endothelial cells, human saphenous vein endothelial cells, and early EPCs, AM stimulation did not increase VEGF secretion or VEGF mRNA expression in late EPCs (8, 13, 23) . In contrast, AM-induced expression of VEGF has been observed in human microvascular endothelial cells and aortic endothelial cells (20, 44) . The expression of VEGFR-2 remained unchanged following AM stimuli in our study, and blocking the VEGFR-2 receptor did not reduce the proangiogenic response of AM stimuli (13) . However, it has been suggested that AM can act through transactivation of VEGFR-2 inducing a proangiogenic signaling cascade (13) . AM has also been reported to act synergistically with VEGF to enhance the angiogenic response of endothelial cells in vitro (8, 20) . Although the combination of the two seemed to increase tubular formation in our study, this result was not significantly different from the effect of either agent alone. Furthermore, AM is reported to suppress VEGFinduced expression of adhesion molecules and leukocyte adhesiveness to endothelial cells, indicating a potential antiinflammatory effect on VEGF-stimulated cells (27) . In contrast to these findings, simultaneous stimulation with AM and VEGF further augmented the expression of the inflammatory cytokine IL-6 in our study.
VEGF increases vascular permeability and edema formation and has been implicated in the development and progression of atherosclerosis, potentially limiting its utility in therapeutic angiogenesis (47, 48) . Thus far, these concerns do not seem to apply with regard to adrenomedullin. Also, apart from the proangiogenic effects, the properties of adrenomedullin are potentially beneficial in the treatment for a number of cardiovascular diseases (53) . This further strengthens its potential for use in conjunction with autologous EPC transplantation for therapeutic angiogenesis.
Stromal cell-derived factor 1 (SDF-1) is a chemokine that is secreted from early EPCs and local administration of SDF-1 enhance recruitment of these cells to sites of ischemia (49, 52) . Late EPCs expressed the SDF-1 receptor CXCR-4, but we could not find any evidence that nonstimulated late EPCs did release SDF-1. As for VEGF, SDF-1 release was unchanged following AM stimuli. Also, there were no observations indicating that these cells altered their susceptibility toward VEGF and SDF-1. Thus, these experiments did not support a chemo-"self" attraction promoted by adrenomedullin.
The release of proangiogenic cytokines and growth factors has been proposed to be an important contributor to the observed effects of transplanted progenitor cells (5, 41, 49) . Some of these secreted factors also possess proinflammatory properties associated with progression of cardiovascular disease, and it has been speculated that some aspects of EPC transplantation could promote atherosclerosis (12, 57) . The cytokines IL-8 and IL-6 are previously shown to stimulate endothelial cell proliferation and act proangiogenic (7, 28, 30, 54) . Studies have also demonstrated that IL-8 contributes substantially to the paracrine mitogenic effects of EPCs (14) . IL-6, on the other hand, seems to increase EPC proliferation and in vitro tubule formation (6) . In line with earlier studies on late EPCs, we found that these cells secrete IL-8 under basal culture conditions (14, 57) . The cultured EPCs, in common with mature endothelial cells, also secreted IL-6 (46). Our observations suggest that adrenomedullin induces an early release of these cytokines. However, this stimulated release was small and transitory, and a substantial proinflammatory effect of adrenomedullin was therefore not observed. An indirect proangiogenic effect of adrenomedullin through increased release of these cytokines cannot, however, be ruled out.
Conclusion. Late outgrowth EPCs express the CRLR/ RAMP-2 (AM1) receptor complex, and our findings suggest that adrenomedullin augments the proangiogenic properties of this highly proliferative progenitor cell population in a similar fashion to that of VEGF. This seemed to be mediated through activation of the PI3K/Akt signaling pathway. Adrenomedullin did not seem to influence the paracrine properties of EPCs, i.e., release of proinflammatory and proangiogenic cytokines and chemokines.
